Tag Archives: Daniel Vasella

Novartis takes total control of Alcon

In a $28Bn USD operation, the Swiss Pharmaceutical buys the 52% of Alcon’s remanent stock from Nestlé. Novartis would own an approximate 77 percent interest in Alcon. The operation goes at least one and a half year earlier than estimated in … Continue reading

Posted in Alta Dirección, Mercadotecnia, Salud | Tagged , , , , , , , , , , , , , , | Leave a comment